Market Place
Sourcing Support
AstraZeneca completes acquisition of Fusion Pharmaceuticals
05 Jun 2024 //
INDIANPHARMAPOST
Acquisition of Fusion Pharmaceuticals Completed
04 Jun 2024 //
PR NEWSWIRE
Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement
31 May 2024 //
PR NEWSWIRE
Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca
29 May 2024 //
PR NEWSWIRE
Fusion Pharma doses first patient in AlphaBreak trial to evaluate FPI-2265
13 May 2024 //
PHARMABIZ
Fusion Pharma FPI-2265 Phase 2 Prostate Cancer Trial Dosed
09 May 2024 //
PR NEWSWIRE
Fusion Pharma Q1 2024 Results, Clinical Program Updates
07 May 2024 //
PR NEWSWIRE
Fusion Pharma Mails Circular, Receives Interim Order for Shareholder Meet
25 Apr 2024 //
PR NEWSWIRE
Fusion Pharmaceuticals Announces Interim Data Presentation
10 Apr 2024 //
PR NEWSWIRE
Fusion Wins 2024 Best Place to Work in Omaha Award, Earns Sixth Plac on the List
20 Mar 2024 //
ACCESSWIRE
Fusion Reports Fourth Quarter and Full Year 2023 Financial Results
20 Mar 2024 //
PR NEWSWIRE
AstraZeneca bets on new cancer treatments with $2 bln Fusion Pharma purchase
19 Mar 2024 //
PR NEWSWIRE
Fusion Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Mar 2024 //
PR NEWSWIRE
Fusion to Present Data from Phase 2 TATCIST Trial Evaluating FPI-2265
05 Mar 2024 //
PR NEWSWIRE
Fusion Pharmaceuticals to Present at Upcoming March Investor Conferences
26 Feb 2024 //
PR NEWSWIRE
Fusion Pharmaceuticals Enters into License Agreement with Heidelberg University
16 Feb 2024 //
PR NEWSWIRE
Fusion Pharmaceuticals to Present at the Oppenheimer 34th Annual Conference
07 Feb 2024 //
PR NEWSWIRE
Fusion Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Feb 2024 //
PR NEWSWIRE
Fusion Pharma marks in-house radiopharma manufacturing success
05 Jan 2024 //
ENDPTS
Fusion Pharmaceuticals Announces Clinical Program and Manufacturing Updates
04 Jan 2024 //
PR NEWSWIRE
Fusion Pharma Strengthens Actinium Supply with Onsite Isotope Production
16 Nov 2023 //
PR NEWSWIRE
BWXT Medical Expands Collaboration with Fusion Pharmaceuticals
16 Nov 2023 //
BUSINESSWIRE
Fusion Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 Nov 2023 //
PR NEWSWIRE
Fusion Pharmaceuticals Announces Third Quarter 2023 Financial Results
07 Nov 2023 //
PR NEWSWIRE
Fusion Pharmaceuticals Appoints Jeremy Bender, Teresa Bitetti and David Meek
16 Oct 2023 //
PR NEWSWIRE
Fusion Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Sep 2023 //
PR NEWSWIRE
Fusion Pharmaceuticals to Present at Upcoming September Investor Conferences
05 Sep 2023 //
PR NEWSWIRE
Fusion Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09 Aug 2023 //
PR NEWSWIRE
Fusion Pharmaceuticals to Present Interim Data from Phase 1 Trial of FPI-1434
26 Jun 2023 //
PR NEWSWIRE
Fusion Pharmaceuticals to Present at the TD Cowen Innovation Summit
16 Jun 2023 //
PR NEWSWIRE
Fusion Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Jun 2023 //
PR NEWSWIRE
Fusion Appoints Chief Clinical Officer and Chief Commercial Officer
02 Jun 2023 //
ACCESSWIRE
Fusion Pharmaceuticals to Present at the Jefferies Healthcare Conference
31 May 2023 //
PR NEWSWIRE
Fusion Pharmaceuticals Announces 1Q 2023FYR &Clinical Program Updates
11 May 2023 //
PR NEWSWIRE
Fusion to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day
09 May 2023 //
PR NEWSWIRE
Fusion Announces Opening of Radiopharmaceutical Manufacturing Facility
02 May 2023 //
PR NEWSWIRE
Fusion Announces Presentation of Preclinical Data Supporting FPI-2059
19 Apr 2023 //
PR NEWSWIRE
Fusion Appoints VP for Sales and Fusion Marketplace, Bringing More Expertise
17 Apr 2023 //
ACCESSWIRE
Fusion Pharmaceuticals Announces IND Clearance for FPI-2068
12 Apr 2023 //
PR NEWSWIRE
Fusion Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Apr 2023 //
PR NEWSWIRE
Fusion Announces First Patient Dosed in Phase 1 Study of FPI-2059
20 Mar 2023 //
PR NEWSWIRE
Fusion Announces Fourth Quarter 2022 Financial Results
16 Mar 2023 //
PR NEWSWIRE
Fusion Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 Mar 2023 //
PR NEWSWIRE
Fusion Pharmaceuticals to Present at the 43rd Annual Cowen Healthcare Conference
02 Mar 2023 //
PR NEWSWIRE
RadioMedix Inc. Announces the Acquisition of its 225Ac-PSMA I&T program
15 Feb 2023 //
GLOBENEWSWIRE
Fusion Pharmaceuticals To Acquire Phase 2 Program For 225Ac-PSMA I&T
13 Feb 2023 //
PRESS RELEASE
Fusion Pharma to Present at the SVB Securities Global Biopharma Conference
13 Feb 2023 //
PR NEWSWIRE
Fusion Pharmaceuticals and BWXT Medical Announce Actinium-225 Partnership
05 Jan 2023 //
BUSINESSWIRE
Fusion Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Jan 2023 //
PRNEWSWIRE
Fusion Announces Inducement Grants Under Nasdaq Listing 5635(c)(4)
09 Nov 2022 //
PRNEWSWIRE
Fusion Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Oct 2022 //
PRNEWSWIRE
Fusion Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 Sep 2022 //
PRNEWSWIRE
Fusion to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
07 Sep 2022 //
PRNEWSWIRE
Fusion Announces First Patient Dosed in Phase 1/2 Study of FPI-1966 In Patients
29 Aug 2022 //
PRNEWSWIRE
Fusion Pharma Q2 2022 Financial Results and Clinical Program Updates
09 Aug 2022 //
PRNEWSWIRE
Fusion Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Aug 2022 //
PRNEWSWIRE
Fusion Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Jul 2022 //
PRNEWSWIRE
Fusion Pharma Announces FDA Clearance of IND for FPI-2059
23 Jun 2022 //
PRNEWSWIRE
Fusion Presents Imaging Data from Cold Ab Sub-Study in PI Study of FPI-1434
14 Jun 2022 //
PRNEWSWIRE
Fusion Pharma to Present at 2022 Bloom Burton & Co. Investor Conference
26 Apr 2022 //
PRNEWSWIRE
